Triagem para o tratamento ambulatorial da neutropenia febril

Abstract

Febrile neutropenia is a frequent and potentially fatal adverse event of chemotherapy. Nowadays, febrile neutropenia is considered an emergency and it is known that prompt infusion of antibiotics decreases mortality. Several studies demonstrated that febrile neutropenia is a heterogeneous group of diseases and that factors such as outpatient status, no hypotension, no dehydration, no chronic obstructive pulmonary disease, no symptoms, no previous fungal infection and age < 60 years are protective factors against serious complications as demonstrated by the Multinational Association for Supportive Care in Cancer (MASCC). These data show that outpatient treatment and early discharge is safer and much research has shown lower costs for outpatient treatment in low-risk patients with febrile neutropenia. The aim of this work is to review and discuss tools (in particular the MASCC index) for safe screening of febrile neutropenia for outpatient treatment in addition to demonstrate results of research.

Febrile neutropenia recurrence after chemotherapy in patients with breast cancer / Neutropenia febril de recorrência pós quimioterapia em paciente com câncer de mama / Febril recurrencia neutropenia después de la quimioterapia en pacientes con cáncer...

“…Na avaliação inicial é preciso analisar o estado oncológico atual, quimioterapia prévia, exame físico minucioso e solicitação de exames laboratoriais (23) .…”

<b>Risk factors in the management of antimicrobial agents in nursing

“…This fact corroborated results in current study since the highest prevalence in the use of antimicrobial drugs was identified in patients from oncological and hematological clinics. According to Bellesso, Costa, Chamone, & Llacer (2010), febrile neutropenia is a complication in chemotherapy-treated patients and may be fatal. Infection risks may increase according to the prolonged period with neutropenia.…”

Comparação entre os biomarcadores inflamatórios procalcitonina (PCT), interleucina-6 (IL-6) e proteína-C reativa (PCR) para diagnóstico infeccioso e evolução de febre em pacientes neutropênicos submetidos a transplante de células tron

“…Ao mesmo tempo, auxilia a identificação de pacientes com baixo risco de complicações que podem ser tratados ambulatorialmente (Kern, 2006). Cabe ressaltar que, para o tratamento ambulatorial da neutropenia febril, é fundamental uma avaliação clínico-laboratorial muito criteriosa, bem como a avaliação socioeconômica e da estrutura da enfermagem para a efetivação do mesmo (Belesso et al, 2010).…”